Investor science event: Getting ahead of respiratory syncytial virus in older adults

After presenting the positive AReSVi-006 pivotal phase III results for our RSV (respiratory syncytial virus) older adults vaccine candidate at IDWeek 2022, GSK management hosted an investor science event on 21 October 2022.

Back to top